Brief: Tetra Bio Pharma Says Submitted Data To U.S. FDA For Surrogate Endpoint To Be Used For An Accelerated Approval For Caumz
19/12/2019 13:53
Dec 19 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIO PHARMA - SUBMITTED DATA TO U.S. FDA FOR
SURROGATE
ENDPOINT TO BE USED FOR AN ACCELERATED APPROVAL FOR CAUMZ
Source text for Eikon: ID:nGNXSSqwK
Further company coverage: TBP.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding